Incidence, as Well as Gender, Age and Ethnic Distribution of Sarcomas in the Republic of Suriname from 1980 to 2008

Mans, Dra; Lall, AE Budhu; Macnack, VL; Tholl, JA van; Zandveld, EB; Vrede, MA

doi:10.7727/wimj.2013.071

Cited by 6 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Still, 28 histologic subtypes were found in the cohort, and the top seven relatively frequent subtypes were leiomyosarcoma (38), liposarcoma (27), fibrosarcoma (16), rhabdomyosarcoma (14), myofibroblastoma (14), epithelioid sarcoma (12), and synovial sarcoma (12) (Table 1 and Figure 1A Top). Consistent with previous research globally, leiomyosarcoma in the cohort was also significantly predominant in female (Female/Male ratio = 5.17) 21,22 …”

Section: Resultssupporting

confidence: 90%

“…Consistent with previous research globally, leiomyosarcoma in the cohort was also significantly predominant in female (Female/Male ratio = 5.17). 21 , 22 …”

Section: Resultsmentioning

confidence: 99%

“…Consistent with previous research globally, leiomyosarcoma in the cohort was also significantly predominant in female (Female/Male ratio = 5.17). 21,22 A total of 2743 GAs in 330 genes were identified in tumor tissue samples, including 979 CNVs, 982 single nucleotide variations (SNVs), 182 indels, and 151 gene fusions (Table S1). The median number of GAs per patient was six in a range from 1 to 38.…”

Section: Molecular Landscapementioning

confidence: 99%

See 2 more Smart Citations

Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients

et al. 2022

View full text Add to dashboard Cite

Background: Soft-tissue sarcoma (STS) is a rare solid malignant tumor with numerous histologic subtypes. Current studies on targeted therapy for STS are in preclinical and early-phase trials. Genomic differences largely influence the prognosis of patients even with the same subtype. To investigate the genomic alterations (GAs) and the potential of targeted therapy in STS, we analyzed the genomic landscape, the therapeutic GAs, and biomarkers of immunotherapy in Chinese STS patients.Methods: Targeted sequencing covering 425 genes was performed, from which we obtained the results of tissue samples from 351 Chinese STS patients of all ages covering different histologic subtypes. Bioinformatics analysis of altered genes with nonsynonymous mutations, copy-number variations, and gene fusions were performed. OncoKB therapeutic GAs and relevant biomarkers including TMB, MSI, and HRD were further examined for potential targeted therapy. Results:In total, 2743 GAs were identified in 330 genes with a median of 6 (1-38) per case. The top 11 frequently altered genes were: TP53, MCL1, MDM2, CDK4, MYC, CDKN2A, GNAS, RB1, ATRX, CDKN2B, and FGFR1. OncoKB defined therapeutic GAs were found in 23 genes in 43% of the patients. In general, 9.4% of the patients had high-TMB, 2.8% had MSI, and 13.7% had HRD. A significant difference in the percentage of patients with OncoKB therapeutic GAs were observed between the most frequent two subtypes, leiomyosarcoma and liposarcoma.Altogether, 54% of the patients had the potential to respond to a targeted therapy. Conclusion:This study indicated the potential efficacy of targeted therapy on many STS patients, and also provided insight for novel precision therapy. The clinical efficacy of combining targeted therapy and immunotherapy can be further investigated.

show abstract

Section: Resultssupporting

confidence: 90%

“…Consistent with previous research globally, leiomyosarcoma in the cohort was also significantly predominant in female (Female/Male ratio = 5.17). 21 , 22 …”

Section: Resultsmentioning

confidence: 99%

Section: Molecular Landscapementioning

confidence: 99%

See 1 more Smart Citation

Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The incidence rate of different sarcoma subtypes varies with sex and age. Classical osteosarcoma and rhabdomyosarcoma frequently occur in children and adolescents, while myxofibrosarcoma, synovial sarcoma, angiosarcoma, DFSP and clear cell sarcoma are more common in patients >20 years of age ( 69 , 70 ). Also, myxofibrosarcoma, rhabdomyosarcoma and synovial sarcoma may be more likely to occur in men, while the occurrence of leiomyosarcoma was notably more common in female participants ( 70 ).…”

Section: Discussionmentioning

confidence: 99%

“…Classical osteosarcoma and rhabdomyosarcoma frequently occur in children and adolescents, while myxofibrosarcoma, synovial sarcoma, angiosarcoma, DFSP and clear cell sarcoma are more common in patients >20 years of age ( 69 , 70 ). Also, myxofibrosarcoma, rhabdomyosarcoma and synovial sarcoma may be more likely to occur in men, while the occurrence of leiomyosarcoma was notably more common in female participants ( 70 ). The results of the present study support previous studies suggesting that osteosarcomas, Ewing's sarcomas, GISTs and liposarcomas are associated with patient age, and that leiomyosarcoma is associated with patient sex.…”

Section: Discussionmentioning

confidence: 99%

Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma

Xie

Shi³

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

Sarcomas represent a heterogeneous group of mesenchymal malignancies arising at various locations in the soft tissue and bone. Though a rare disease, sarcoma affects ~200,000 patients worldwide every year. The prognosis of patients with sarcoma is poor, and targeted therapy options are limited; therefore, accurate diagnosis and classification are essential for effective treatment. Sarcoma samples were acquired from 199 patients, in which TP53 (39.70%, 79/199), CDKN2A (19.10%, 38/199), CDKN2B (15.08%, 30/199), KIT (14.07%, 28/199), ATRX (10.05%, 20/199) and RB1 (10.05%, 20/199) were identified as the most commonly mutated genes (>10% incidence). Among 64 soft-tissue sarcomas that were unclassified by immunohistochemistry, 15 (23.44%, 15/64) were subsequently classified using next-generation sequencing (NGS). For the most part, the sarcoma subtypes were evenly distributed between male and female patients, while a significant association with sex was detected in leiomyosarcomas. Statistical analysis showed that osteosarcoma, Ewing's sarcoma, gastrointestinal stromal tumors and liposarcoma were all significantly associated with the patient age, and that angiosarcoma was significantly associated with high tumor mutational burden. Furthermore, serially mutated genes associated with myxofibrosarcoma, gastrointestinal stromal tumor, osteosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma and Ewing's sarcoma were identified, as well as neurotrophic tropomyosin-related kinase ( NTRK) fusions of IRF2BP2-NTRK1, MEF2A-NTRK3 and ITFG1-NTRK3 . Collectively, the results of the present study suggest that NGS-targeting provides potential new biomarkers for sarcoma diagnosis, and may guide more precise therapeutic strategies for patients with bone and soft-tissue sarcomas.

show abstract

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy

Liu¹,

Liu

2018

Medicine

View full text Add to dashboard Cite

Aim:To make an accurate estimation of the association of ERCC1 and ERCC2 polymorphisms with osteosarcoma (OS) prognosis in Chinese population.Methods:Total 7 qualified studies with 1404 osteosarcoma patients were included. Odds ratios (OR) with 95% CIs were pooled for the survival rate in different osteosarcoma patients with ERCC1 and ERCC2 genetic polymorphisms. The heterogeneity was assessed by I2 test. Potential publication bias was assessed by Begg funnel plot and Egger linear regression test.Results:In rs11615, no significant association was found under dominant [TT+TC vs. CC: OR = 1.252, 95% CI:0.864–1.815, P = .235], recessive [TT vs. TC+CC: OR = 0.850, 95% CI: 0.695–1.030, P = .095] or allelic model [T vs. C Allele: OR = 1.219, 95% CI: 0.922–1.612, P = .165]. In rs13181, no significant association was found under dominant [AA+AC vs. CC: OR = 1.031, 95% CI: 0.800–1.329, P = .801], recessive [AA vs. AC+CC: OR = 1.005, 95% CI: 0.875, 1.154, P = .944] or allelic model [A vs. C Allele: OR = 1.009, 95% CI: 0.903–1.128, P = .870]. In rs1799793, no significant association was found under dominant [GG+GA vs. AA: OR = 1.134, 95% CI: 0.884–1.454, P = .322, recessive [GG vs. AG+AA: OR = 1.025, 95% CI: 0.881–1.192, P = .750], or allelic model [G vs. A Allele: OR = 1.046, 95% CI: 0.930–1.177, P = .450].Conclusion:This study did not support rs11615, rs13181 or rs1799793 to be used as surrogate markers for clinical outcome of osteosarcoma with chemotherapy.

show abstract

Incidence, as Well as Gender, Age and Ethnic Distribution of Sarcomas in the Republic of Suriname from 1980 to 2008

Abstract: The incidence of sarcomas in Suriname, and their gender, age and ethnic distribution in general, seemed comparable with international data. The main exception might be leiomyosarcoma which might have a predilection for Afro-Surinamese.

Cited by 6 publications

References 22 publications

Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients

Molecular landscape and therapeutic alterations in Asian soft‐tissue sarcoma patients

Potential application of genomic profiling for the diagnosis and treatment of patients with sarcoma

Genetic polymorphisms of ERCC-1 and ERCC-2 are not prognostic markers in osteosarcoma patients with chemotherapy

Contact Info

Product

Resources

About